Form 4: Veracyte Chief Scientific & Medical Officer Reports Routine Stock Transaction for Tax Obligations

Veracyte's Chief Scientific & Medical Officer, Phillip G. Febbo, reported a disposition of 2,955 shares of common stock, valued at $26.74 per share, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Phillip G. Febbo, Veracyte, Inc.'s Chief Scientific & Medical Officer, filed a Form 4 reporting a transaction on June 2, 2025.
• The transaction involved the disposition of 2,955 shares of Veracyte common stock at a price of $26.74 per share.
• This disposition was specifically for the purpose of satisfying tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The shares withheld consisted of 1,688 shares related to the vesting of 3,324 RSUs granted on October 2, 2023, and 1,267 shares related to the vesting of 2,494 RSUs granted on March 6, 2024.
• The filing explicitly states that this transaction does not represent a sale by the reporting person.
• Following this transaction, Phillip G. Febbo beneficially owns 103,745 shares of Veracyte common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes related to executive compensation, with no direct positive or negative implications for the company's operational or financial performance.

Positives

• The underlying event for the transaction is the vesting of Restricted Stock Units, which represents a positive compensation event for the executive.
• The transaction is a standard and expected procedure for covering tax liabilities upon RSU vesting, indicating proper financial management by the executive.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to executive compensation. It does not provide broader insights into industry trends or competitive landscape, as it focuses solely on an individual's stock ownership changes.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and not a market sale. It reflects the vesting of previously granted equity compensation.

Key Dates

Keywords

Veracyte, VCYT, SEC Form 4, Insider Transaction, Stock Ownership, Executive Compensation, Restricted Stock Units, Tax Withholding